Find Reports

Select Report Type

Reimbursement Review

Displaying 376 - 400 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
apomorphine hydrochloride	Kynmobi	apomorphine hydrochloride	SR0650 Kynmobi - CDEC Final Recommendation February 26, 2021_For posting.pdf sr0650-kynmobi-clinical-review-report.pdf sr0650-kynmobi-pharmacoeconomic-review-report.pdf Kynmobi - Patient Group Input_For Posting.pdf	Parkinson’s disease	Reimburse with clinical criteria and/or conditions	Complete	Jun 25, 2020	Feb 24, 2021	SR0650-000
nintedanib	Ofev	nintedanib	SR0654 Ofev - Final CDEC Recommendation February 26, 2021_For Posting.pdf sr0654-ofev-clinical-review-report.pdf sr0654-ofev-pharmacoeconomic-review-report.pdf SR0654 Ofev - Consolidated Patient Input for Posting.pdf	chronic fibrosing interstitial lung diseases	Reimburse with clinical criteria and/or conditions	Complete	Jul 24, 2020	Feb 24, 2021	SR0654-000
Levetiracetam	pdp-levETIRAcetam	Levetiracetam	SR0653 pdp-levETIRAcetam - CDEC Final Recommendation February 8, 2021_For Posting.pdf sr0653-pdp-levETIRAcetam-clinical-and-economic-review-report.pdf	Epilepsy	Reimburse with clinical criteria and/or conditions	Complete	Jul 17, 2020	Feb 3, 2021	SR0653-000
Entrectinib (Rozlytrek) for RO...	Rozlytrek	Entrectinib	10206EntrectinibROS1NSCLC_FnRec_EarlyConv_ApprovedbyChair_EC27Jan2021_final.pdf 10206EntrectinibROS1NSCLC_fnEGR_NOREDACT-ABBREV_EC27Jan2021_final.pdf 10206EntrectinibROS1NSCLC_fnCGR_REDACT_EC27Jan2021_final.pdf 10206EntrectinibROS1NSCLC_InRec_approvedbyChair_Post08Jan2021_final.pdf 10206EntrectinibROS1NSCLC_PAG Feedback_EC27Jan2021_final.pdf 10206EntrectinibROS1NSCLC_SponsorFeedback_27Jan2021_final.pdf 10206EntrectinibROS1NSCLC_PatientFeedback_LCC_Post27Jan2021_final.pdf 10206EntrectinibROS1NSCLC_Combined_ClinicianFeedback_EC27Jan2021_final.pdf 10206EntrectinibROS1NSCLC_Patient_COI_LCC_EC27Jan2021_final.pdf 10206EntrectinibROS1NSCLC_Clinician_COI_Redacted.pdf	ROS1-positive NSCLC	Reimburse with clinical criteria and/or conditions	Complete	Jan 8, 2020	Jan 27, 2021	PC0206-000
vedolizumab	Entyvio	vedolizumab	SR0647 Entyvio - CDEC Final Recommendation January 22, 2021_for posting.pdf sr0647-entyvio-clinical-economic-review-report.pdf SR0647_Entyvio_PI Submission.pdf	Crohn’s disease	Reimburse with clinical criteria and/or conditions	Complete	Jul 23, 2020	Jan 21, 2021	SR0647-000
Acalabrutinib (Calquence) for ...	Calquence	Acalabrutinib	10210AcalabrutinibCLL(previously untreated)_FnRec_pERC Chair Approved_REDACT_Post08Jan2021_final.pdf 10210AcalabrutinibCLL(previously untreated)_fnEGR_REDACTABBREV_Post08Jan2021_final.pdf 10210AcalabrutinibCLL(previously untreated)_fnCGR_REDACT_Post08Jan2021_final.pdf 10210AcalabrutinibCLL(previously untreated)_inRec_pERC Chair Approved_REDACT_Post29Oct2020_final.pdf 10210AcalabrutinibCLL(previously untreated)_PAGFeedbackSummary_Post08Jan2021_final.pdf 10210AcalabrutinibCLL(previously untreated)_SponsorFeedback_Post08Jan2021_final.pdf 10210AcalabrutinibCLL(previously untreated)_PatientFeedback_CLLPAG_Post08Jan2021_final.pdf 10210AcalabrutinibCLL(previously untreated)_ClinicianFeedback_CCO_Post08Jan2021_final.pdf 10210AcalabrutinibCLL(previously untreated)_COIs_LC_Post08Jan2021_final.pdf 10210AcalabrutinibCLL(previously untreated)_Combined COIs_Post08Jan2021_final_Redacted.pdf	Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)	Reimburse with clinical criteria and/or conditions	Complete	Apr 7, 2020	Jan 8, 2021	PC0210-000
Glasdegib (Daurismo) for acute...	Daurismo	Glasdegib	10207GlasdegibAML_FnRec_approvedbyChair_REDACT_Post08Jan2021_final.pdf 10207GlasdegibAML_fnEGR_NOREDACT-ABBREV_Post08Jan2021_final.pdf 10207GlasdegibAML_fnCGR_REDACT_Post08Jan2021_final.pdf 10207GlasdegibAML_inRec_approvedbyChair.REDACT_Post29Oct2020_final.pdf 10207GlasdegibAML_PAGFeedbackSummary_Post08Jan2021_final.pdf 10207GlasdegibAML_SponsorFeedback_Post08Jan2021_final.pdf 10207GlasdegibAML_PatientFeedback_Post08Jan2021_final.pdf 10207GlasdegibAML_Combined_ClinicianFeedback_Post08Jan2021_final.pdf 10207GlasdegibAML_COI_LLSC_Post08Jan2021_final.pdf 10207GlasdegibAML_ClinicianInput_Combined_COIs_Post08Jan2021_final.pdf	Acute Myeloid Leukemia (AML)	Do not reimburse	Complete	May 6, 2020	Jan 8, 2021	PC0207-000
dapagliflozin	Forxiga	dapagliflozin	SR0642 Forxiga - CDEC Final Recommendation January 21, 2021_revised_redacted_for posting.pdf sr0642-forxiga-clinical-review-report.pdf sr0642-forxiga-pharmacoeconomic-review-report.pdf SR0642_Forxiga_PI Submission.pdf	Heart failure with reduced ejection fraction	Reimburse with clinical criteria and/or conditions	Complete	Mar 31, 2020	Dec 23, 2020	SR0642-000
Pembrolizumab (Keytruda) for H...	Keytruda	Pembrolizumab	10216PembrolizumabHNSCC_FnRec_EC22Dec2020_final.pdf 10216PembrolizumabHNSCC_fnEGR_REDACTABBREV_EC22Dec2020_final.pdf 10216PembrolizumabHNSCC_fnCGR_REDACT_EC22Dec2020_final.pdf 10216PembrolizumabHNSCC_InRec_approvedbyChair_Post03Dec2020_final.pdf 10216PembrolizumabHNSCC_PAGFeedbackSummary_EC22Dec2020_final.pdf 10216PembrolizumabHNSCC_SponsorFeedback_EC22Dec2020_final.pdf media:document:957f66ab-89b6-4344-8d88-8041b0f4399f 10216PembrolizumabHNSCC_ClinicianFeedback_CCO_EC22Dec2020_final.pdf 10216PembrolizumabHNSCC_Patient_COI_LSTN_22EC22Dec2020_final.pdf 10216PembrolizumabHNSCC_Combined_Clinician COIs_EC22Dec2020_final.pdf	head and neck squamous cell carcinoma (HNSCC)	Reimburse with clinical criteria and/or conditions	Complete	May 1, 2020	Dec 22, 2020	PC0216-000
emicizumab	Hemlibra	emicizumab	ST0651 Hemlibra - CPEC Final Recommendation December 23, 2020_for posting.pdf st0651-hemlibra-clinical-review-report.pdf st0651-hemlibra-pharmacoeconomic-review-report.pdf Hemlibra - Patient Group Input_For Posting.pdf	Bleeding prevention, hemophilia A	Reimburse with clinical criteria and/or conditions	Complete	Jun 30, 2020	Dec 21, 2020	ST0651-000
esketamine hydrochloride	Spravato	esketamine hydrochloride	SR0621 Spravato - CDEC Final Recommendation December 18, 2020_for posting.pdf sr0621-spravato-clinical-review-report.pdf sr0621-spravato-pharmacoeconomic-review-report.pdf SR0621_Esketamine_PI Submission.pdf	Major depressive disorder (MDD), adults	Do not reimburse	Complete	Jun 24, 2019	Dec 16, 2020	SR0621-000
Brentuximab Vedotin (Adcetris)...	Adcetris	Brentuximab Vedotin	10213BrentuximabVedotinpcALCLMF_fnRec_Post03Dec2020_final.pdf 10213BrentuximabVedotinpcALCLMF_fnEGR_NOREDACTABBREV_03Dec2020_final.pdf 10213BrentuximabVedotinpcALCLMF_fnCGR_NOREDACT_Post03Dec2020_final.pdf 10213BrentuximabVedotinpcALCLMF_inRec_01Oct2020_Post_final.pdf 10213BrentuximabVedotinpcALCLMF_PAGFeedbackSummary_Post03Dec2020_final.pdf 10213BrentuximabVedotinpcALCLMF_SponsorFeedback_Post03Dec2020_final.pdf media:document:efdf78b7-49cd-4223-94ca-c798bdf61a9b 10213BrentuximabVedotinpcALCLMF_ClinicianFeedback_CCO_Post03Dec2020_final_Redacted.pdf 10213BrentuximabVedotinpcALCLMF_PatientCOIs_Post03Dec2020_final.pdf 10213BrentuximabVedotinpcALCLMF_Clinician COI_Post03Dec2020_final.pdf	Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF)	Reimburse with clinical criteria and/or conditions	Complete	Mar 30, 2020	Dec 3, 2020	PC0213-000
Brentuximab Vedotin (Adcetris)...	Adcetris	Brentuximab Vedotin	10214BrentuximabVedotinHLAVD_FnRec_approvedbyChair_REDACT_Post03Dec2020_final.pdf 10214BrentuximabVedotinHLAVD_fnEGR_NOREDACT-ABBREV_03Dec2020_final.pdf 10214BrentuximabVedotinHLAVD_fnCGR_REDACT_Post03Dec2020_final.pdf 10214BrentuximabVedotinHLAVD_inRec_Post15Oct2020_final.pdf 10214BrentuximabVedotinHLAVD_PAGFeedbackSummary_Post03Dec2020_final.pdf 10214BrentuximabVedotinHLAVD_SponsorFeedback_Post03Dec2020_final_Redacted.pdf 10214BrentuximabVedotinHLAVD_ClinicianFeedback_CCO_Post03Dec2020_final_Redacted.pdf 10214BrentuximabVedotinHLAVD_Patient COIs_Post03Dec2020_final.pdf 10214BrentuximabVedotinHLAVD_Combined_Clinician COIs_Post03Dec2020_final.pdf	Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)	Reimburse with clinical criteria and/or conditions	Complete	Apr 2, 2020	Dec 3, 2020	PC0214-000
indacaterol /mometasone furoat...	Atectura Breezhaler	indacaterol /mometasone furoate	SR0646 Atectura Breezhaler - CDEC Final CDEC Recommendation November 26, 2020_for posting.pdf sr0646-atectura-breezhaler-clinical-review-report.pdf sr0646-atectura-breezhaler-pharmacoeconomic-review-report.pdf SR0646 Atectura Breezhaler - Patient Group Input_for posting.pdf	Asthma maintenance (adults, children 12 or older)	Reimburse with clinical criteria and/or conditions	Complete	May 19, 2020	Nov 24, 2020	SR0646-000
Indacaterol glycopyrronium m...	Enerzair Breezhaler	indacaterol glycopyrronium mometasone furoate	SR0645 Enerzair Breezhaler - CDEC Final Recommendation November 26, 2020_for posting.pdf sr0645-enerzair-breezhaler-clinical-review-report.pdf sr0645-enerzair-breezhaler-pharmaceconomic-review-report.pdf Indacaterol glycopyrronium mometasone furoate - Patient Group Input June 4, 2020.pdf	Asthma maintenance, adults	Reimburse with clinical criteria and/or conditions	Complete	May 19, 2020	Nov 24, 2020	SR0645-000
Tecentriq & Avastin for He...	Tecentriq & Avastin	Atezolizumab & Bevacizumab	10217AtezolizumabBevacizumabHCC_fnRec_EC_Post17Nov2020_final.pdf 10217AtezolizumabBevacizumabHCC_fnEGR_REDACTABBREV_EC_Post17Nov2020_final.pdf 10217AtezolizumabBevacizumabHCC_fnCGR_REDACT_PostEC17Nov2020_final.pdf 10217AtezolizumabBevacizumabHCC_inRec_ApprovedByChair_REDACT_Post29Oct2020_final.pdf 10217AtezolizumabBevacizumabHCC_PAGFeedbackSummary_EC_Post17Nov2020_finalRedacted.pdf 10217AtezolizumabBevacizumabHCC_SponsorFeedback_EC_Post17Nov2020_final.pdf media:document:db05592a-2710-4893-b072-d9cd9379459d 10217AtezolizumabBevacizumabHCC_Combined ClinicianFeedback_EC_Post17Nov2020_final.pdf 10217AtezolizumabBevacizumabHCC_PatientCOIs_Combined_EC_Post17Nov2020_final.pdf 10217AtezolizumabBevacizumabHCC_Clinician COIs_Combined_EC_Post17Nov2020_final_Redacted.pdf	Hepatocellular Carcinoma (HCC)	Reimburse with clinical criteria and/or conditions	Complete	May 21, 2020	Nov 17, 2020	PC0217-000
Venetoclax (Venclexta) in comb...	Venclexta	Venetoclax Obinutuzumab	10212VenetoclaxObinutuzumabCLL_fnRec_EC_Post17Nov2020_final.pdf 10212VenetoclaxObinutuzumabCLL_fnEGR_NOREDACTABBREV_EC_Post17Nov2020_final.pdf 10212VenetoclaxObinutuzumabCLL_fnCGR_REDACT_EC_Post17Nov2020_final.pdf 10212VenetoclaxObinutuzumabCLL_inRec_Post29Oct2020_final.pdf 10212VenetoclaxObinutuzumabCLL_PAGFeedbackSummary_EC_Post17Nov2020_final.pdf 10212VenetoclaxObinutuzumabCLL_SponsorFeedback_EC_Post17Nov2020_final.pdf 10212VenetoclaxObinutuzumabCLL_PatientFeedback_CLLPAG_EC_Post17Nov2020_final.pdf 10212VenetoclaxObinutuzumabCLL_ClinicianFeedback_CCO_EC_Post17Nov2020_final.pdf 10212VenetoclaxObinutuzumabCLL_Patient COIs_EC_Post17Nov2020_final.pdf 10212VenetoclaxObinutuzumabCLL_Clinician Combined_COIs EC_Post17Nov2020_final_Redacted.pdf	Obinutuzumab for CLL	Reimburse with clinical criteria and/or conditions	Complete	Apr 17, 2020	Nov 17, 2020	PC0212-000
Acalabrutinib (Calquence) for ...	Calquence	Acalabrutinib	10211AcalabrutinibCLL_fnRec_REDACT_EC_Post17Nov2020_final.pdf 10211AcalabrutinibCLL_fnEGR_REDACTABBREV_EC_Post17Nov2020_final.pdf 10211AcalabrutinibCLL_fnCGR_REDACT_EC_Post17Nov2020_final_v2.pdf 10211AcalabrutinibCLL_inRec_pERC Chair Approved_REDACT_Post29Oct2020_final.pdf 10211AcalabrutinibCLL_PAGFeedbackSummary_EC_Post17Nov2020_final.pdf 10211AcalabrutinibCLL_SponsorFeedback_EC_Post_17Nov2020_final.pdf 10211AcalabrutinibCLL_PatientFeedback_CLLPAG_EC_Post17Nov2020_final.pdf 10211AcalabrutinibCLL_ClinicianFeedback_CCO_EC_Post17Nov2020_final.pdf 10211AcalabrutinibCLL_COIs_EC_Post17Nov2020_final.pdf 10211AcalabrutinibCLL_Combined Clinician COIs_EC_Post17Nov2020_final_Redacted.pdf	Chronic Lymphocytic Leukemia (CLL)	Reimburse with clinical criteria and/or conditions	Complete	Apr 7, 2020	Nov 17, 2020	PC0211-000
voretigene neparvovec	Luxturna	voretigene neparvovec	SG0643 Luxturna - CDEC Final Recommendation November 16, 2020_for posting.pdf sg0643-luxturna-clinical-review-report.pdf sg0643-luxturna-pharmacoeconomic-review-report.pdf sg0643-luxturna-ethics-review-report.pdf Luxturna - Patient Group Input_For Posting.pdf	Vision loss, inherited retinal dystrophy	Reimburse with clinical criteria and/or conditions	Complete	Apr 23, 2020	Nov 12, 2020	SG0643-000
Blincyto for MRD-positive B-ce...	Blincyto	Blinatumomab	10204BlinatumomabMRD+BCPALL_fnREC_approvedbyChair_REDACT_Post29Oct2020_final.pdf 10204BlinatumomabMRD+BCPALL_fnEGR_NOREDACTABBREV_Post29Oct2020_final.pdf 10204BlinatumomabMRD+BCPALL_fnCGR_REDACT_Post29Oct2020_final.pdf 10204BlinatumomabMRD+BCPALL_inREC_ApprovedbyChair_REDACT_Post_03Sep2020_final.pdf 10204BlinatumomabMRD+BCPALL_PAGFeedbackSummary_Post29Oct2020_final.pdf 10204BlinatumomabMRD+BCPALL_SponsorFeedback_Post29Oct2020_final.pdf 10204BlinatumomabMRD+BCPALL_PatientGroupFeedback_Ac2orn_Post29Oct2020_final.pdf 10204BlinatumomabMRD+BCPALL_ClinicianFeedback_Combined_Post29Oct2020_final.pdf 10204BlinatumomabMRD+BCPALL_PtGrp Combined COIs_Post29Oct2020_final.pdf 10204BlinatumomabMRD+BCPALL_Combined COIs_Post29Oct2020_Redacted.pdf	MRD+ ALL Resubmission	Reimburse with clinical criteria and/or conditions	Complete	Jan 20, 2020	Oct 29, 2020	PC0204-000
budesonide	Jorveza	budesonide	SR0634 Jorveza - CDEC Final Recommendation October 30, 2020_for posting.pdf sr0634-jorveza-clinical-review-report.pdf sr0634-jorveza-pharmacoeconomic-review-report.pdf SR0634_Jorveza_PI_Submission.pdf	Eosinophilic esophagitis, adults	Reimburse with clinical criteria and/or conditions	Complete	Nov 8, 2019	Oct 28, 2020	SR0634-000
Halobetasol propionate and taz...	Duobrii	Halobetasol propionate and tazarotene	SR0638 Duobrii - CDEC Final Recommendation October 30, 2020_For Posting.pdf sr0638-duobrii-clinical-review-report.pdf sr0638-duobrii-parmacoeconomic-review-report.pdf SR0638 Duobrii - Patient Input_For posting.pdf	Psoriasis, moderate to severe plaque	Reimburse with clinical criteria and/or conditions	Complete	Jan 24, 2020	Oct 28, 2020	SR0638-000
etonogestrel	Nexplanon	etonogestrel	SR0648 Nexplanon - CDEC Final Recommendation October 22, 2020_for posting.pdf sr0648-nexplanon-clinical-review-report.pdf sr0648-nexplanon-pharmacoeconomic-review-report.pdf	Prevention of pregnancy	Reimburse with clinical criteria and/or conditions	Complete	Jun 3, 2020	Oct 20, 2020	SR0648-000
eculizumab	Soliris	eculizumab	SR0605 Soliris MG - CDEC Final Recommendation October 21, 2020_for posting.pdf sr0605-soliris-mg-clinical-review-report.pdf sr0605-soliris-mg-pharmacoeconomic-review-report.pdf SR0605_Soliris MG_PI Submission.pdf	Myasthenia Gravis (gMG), adults	Reimburse with clinical criteria and/or conditions	Complete	Apr 1, 2020	Oct 19, 2020	SR0605-000
Enzalutamide (Xtandi) for Meta...	Xtandi	Enzalutamide	10209EnzalutamidemCSPC_fnRec_EarlyConv_REDACT_ApprovedbyChair_Post23Sep2020_final.pdf 10209EnzalutamidemCSPC_fnEGR_REDACT-ABBREV_Post_23Sep2020_final.pdf 10209EnzalutamidemCSPC_fnCGR_REDACT_Post_23Sep2020_final.pdf 10209EnzalutamidemCSPC_inRec_approvedbyChair_REDACT_Post_03Sep2020_final.pdf 10209EnzalutamidemCSPC_PAGFeedbackSummary_Post_23Sep2020_final.pdf 10209EnzalutamidemCSPC_SponsorFeedback_Post_23Sep2020_final.pdf 10209EnzalutamidemCSPC_ClinicianFeedback_CCO_Post_23Sep2020_final.pdf 10209EnzalutamidemCSPC_COI_CCS_Post_23Sep2020_final.pdf Enzalutamide (Xtandi) mCSPC – PAG Feedback on Initial Recommendation - Feedback Enzalutamide (Xtandi) mCSPC – Clinician COI Declarations	mHSPC	Reimburse with clinical criteria and/or conditions	Complete	Feb 24, 2020	Sep 23, 2020	PC0209-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 376 - 400 of 602

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Interventions to Address and Prevent Violence Toward Health Care Workers in the Emergency Department	Interventions to Address and Prevent Violence Toward Health Care Workers in the…	Jun 24, 2021	Rapid Review	Active	RC1362
Hybrid Closed-Loop Insulin Delivery Systems for People with Type 1 Diabetes	OP0548 HCL Rec v. 7.0-pw.pdf op0548-hcl-consolidated-report-appendices-7.0.pdf de0104-hcl-insulin-scoping-brief-final.pdf op0548-hybrid-closed-loop-insulin-for-t1dm-update.pdf op0548-hybrid-close-loop-he-protocol-amendment-sep14.pdf	Jun 23, 2021	Optimal Use	Complete	OP0548-000
Laxatives and Erectile Dysfunction Medications to Treat Side Effects of Opioid Agonist and Methadone Maintenance Therapy	RC1364-OAT Final.pdf	Jun 22, 2021	Rapid Review	Completed	RC1364-000
Extracorporeal Membrane Oxygenation for Adults and Children with Severe Respiratory Failure: A Qualitative Rapid Review	Extracorporeal Membrane Oxygenation for Adults and Children with Severe Respira…	Jun 22, 2021	Rapid Review		RC1365-000
Smoke-Free Hospital Grounds	Smoke-Free Hospital Grounds	Jun 18, 2021	Policy Insight	Completed	CY0010-000
Artificial Intelligence and Machine Learning in Mental Health Services: A Literature Review	artificial_intelligence_and_machine_learning_in_mental_health_services_literature_review.pdf	Jun 14, 2021	Rapid Review	Completed	RC1194-000
Artificial Intelligence and Machine Learning in Mental Health Services: An Environmental Scan	artificial_intelligence_and_machine_learning_in_mental_health_services_environmental_scan.pdf	Jun 14, 2021	Environmental Scan	Completed	ES0343-000
Treatment Programs for Substance Use Disorder	Treatment Programs for Substance Use Disorder	Jun 8, 2021	Summary with Critical Appraisal	Completed	RC1360-000
Conventional Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis	RC1359 csDMARDs for the Treatment of RA Final.pdf	Jun 3, 2021	Rapid Review	Completed	RC1359-000
Abiraterone Acetate for Metastatic Castrate Sensitive Prostate Cancer	Abiraterone Acetate for Metastatic Castrate Sensitive Prostate Cancer	Jun 2, 2021	Peer-reviewed Summary with Critical Appraisal	Completed	RD0060-000
Bisphosphonate Drugs for the Treatment of Osteoporosis in Post-Menopausal Women	he0023-drugs-for-osteoporosis-protocol.pdf Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Wome	Jun 1, 2021	Technology Review	Completed	HE0023-000
Evidence Update on Direct Oral Anticoagulants for Atrial Fibrillation	Direct Oral Anticoagulants for Atrial Fibrillation	May 27, 2021	Technology Review	Completed	HC0018-000
Single-Entry Models in Surgical Services	Single-Entry Models in Surgical Services (Policy Insight)	May 26, 2021	Policy Insight	Completed	CY0009-000
Visual Examination Frequency for People Taking Ethambutol for Tuberculosis	Visual Examination Frequency for People Taking Ethambutol for Tuberculosis	May 25, 2021	Summary with Critical Appraisal	Completed	RC1343-000
Tuberculosis Screening for People with Chronic Conditions	Tuberculosis Screening for People with Chronic Conditions	May 13, 2021	Summary with Critical Appraisal	Completed	RC1345-000
Overview of Formulary Management Practices of Publicly Funded Provincial and Territorial Drug Plans	Overview of Formulary Management Practices of Publicly Funded Provincial and Te…	May 12, 2021	Environmental Scan	Completed	ES0354-000
Analysis of FPT Formulary Harmonization: Specialty Care Medications	Analysis of FPT Formulary Harmonization: Specialty Care Medications	May 12, 2021	Technology Review	Completed	HD0005-000
Electronic Aids to Daily Living	ES0346 Funding and Access to EADLs Final.pdf	May 6, 2021	Environmental Scan	Completed	ES0346-000
Treat and Release for Patients Requiring Emergency Medical Services	RC1358 Treat and release - Final.pdf	May 5, 2021	Summary with Critical Appraisal		RC1358-000
Interferon Gamma Release Assay for Identifying Latent Tuberculosis Infection in People With Bacillus Calmette-Guérin Vaccination	RC1346 draft Final.pdf	May 5, 2021	Summary with Critical Appraisal	Completed	RC1346-000
Bupropion for Major Depressive Disorder or Persistent Depressive Disorder (Dysthymia)	Bupropion for Major Depressive Disorder or Persistent Depressive Disorder (Dyst…	Apr 26, 2021	Summary with Critical Appraisal	Completed	RC1352-000
Onabotulinum Toxin A (Botox) for Spasticity in Patients With Acquired Brain Injury	Onabotulinum Toxin A (Botox) for Spasticity in Patients With Acquired Brain Inj…	Apr 26, 2021	Summary with Critical Appraisal		RC1353-000
Non-Pharmacological Interventions for the Management of Concussion	de0100-concussion-scoping-summary.pdf	Apr 21, 2021	Scoping	Completed	DE0100-000
Rituximab to Treat Primary Membranous Nephropathy	Rituximab to Treat Primary Membranous Nephropathy - Project Protocol Rituximab to Treat Primary Membranous Nephropathy - Report Rituximab to Treat Primary Membranous Nephropathy - Appendix 11	Apr 20, 2021	Health Technology Assessment	Completed	HT0032-000 - HS0001-000
Tuberculosis Stigma and Racism, Colonialism, and Migration: A Rapid Qualitative Review	Tuberculosis Stigma and Racism, Colonialism, and Migration: A Rapid Qualitative…	Apr 19, 2021	Summary with Critical Appraisal	Completed	RC1350-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 376 - 400 of 2138

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Rivaroxaban (granules for oral suspension)			Jul 24, 2024	Reimbursement Review		Not filed	NS0022-000
glecaprevir / pibrentasvir			Jul 24, 2024	Reimbursement Review		Not filed	NS0023-000
clofarabine			Jul 24, 2024	Reimbursement Review		Not filed	NS0020-000
dapagliflozin			Jul 24, 2024	Reimbursement Review		Not filed	NS0021-000
talazoparib			Jul 24, 2024	Reimbursement Review		Not filed	NS0017-000
mepolizumab			Jul 24, 2024	Reimbursement Review		Not filed	NS0018-000
galcanezumab			Jul 24, 2024	Reimbursement Review		Not filed	NS0019-000
vorinostat			Jul 24, 2024	Reimbursement Review		Not filed	NS0015-000
baloxavir marboxil			Jul 24, 2024	Reimbursement Review		Not filed	NS0016-000
icatibant			Jul 24, 2024	Reimbursement Review		Not filed	NS0014-000
olaparib			Jul 24, 2024	Reimbursement Review		Not filed	NS0013-000
lutetium vipivotide tetraxetan		Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jul 24, 2024	Reimbursement Review		Complete	PC0297-000
selpercatinib		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jul 24, 2024	Reimbursement Review		Complete	PC0264-000
Opioid Analgesics to Treat Chronic Noncancer Pain among Patients Prescribed Opioid Agonist Therapy or With Opioid Use Disorder	Our systematic review examined 5 observational studies on the safety of opioid analgesics alone or with opioid agonist therapy for chronic pain in patients with opioid use disorder or a history of opioid use disorder.	Summary Report Final Report Supplemental Document Project Protocol	Jul 23, 2024	Health Technology Review	Systematic Review	Completed	RE0045-000
estradiol and progesterone		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Jul 23, 2024	Reimbursement Review		Complete	SR0697-000
amifampridine		SR0660 Ruzurgi - CDEC Final Recommendation April 23, 2021_For posting.pdf sr0660-ruzurgi-clinical-review-report.pdf sr0660-ruzurgi-pharmacoeconomic-review-report.pdf	Jul 23, 2024	Reimbursement Review		Complete	SR0660-000
cannabidiol		Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation	Jul 23, 2024	Reimbursement Review		Complete	SR0798-000
inebilizumab		Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Jul 23, 2024	Reimbursement Review		Complete	SR0793-000
dexamethasone intravitreal implant		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Jul 23, 2024	Reimbursement Review		Complete	SR0739-000
upadacitinib		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Jul 23, 2024	Reimbursement Review		Complete	SR0730-000
Auditory Verbal Therapy for Children with Hearing Loss		Auditory Verbal Therapy for Children with Hearing Loss	Jul 19, 2024	Health Technology Review	Rapid Review	Completed	RC1542-000
Optimizing ultrasound booking schedules			Jul 16, 2024	Health Technology Review		In Progress	CM0021-000
Somatropin		Final Report	Jul 12, 2024	Health Technology Review	Technology Review	Completed	HC0068-000
Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy	Our utilization analysis examines the market share and drug expenditures of targeted immune modulators for inflammatory bowel disease across public drug plans in Canada.	Final Report	Jul 11, 2024	Health Technology Review	Technology Review	Complete	HC0063-000
fidaxomicin			Jul 11, 2024	Reimbursement Review		Withdrawn	SF0847-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81